Celgene to allow sale of generic Revlimid before patent expiry

December 22, 2015 10:00 PM

35 0

Celgene Corp said it would allow the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States more than a year before the drug's patent expires.

The company said it would allow India-based Natco Pharma Ltd and its U.S. partner to market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement.

Read more

To category page